FA Research Alliance Petitioning for Urgent Access to Omaveloxolone

FA Research Alliance Petitioning for Urgent Access to Omaveloxolone

282221

FA Research Alliance Petitioning for Urgent Access to Omaveloxolone

With backing from a petition that is now circulating online, the Friedrich’s Ataxia Research Alliance (FARA) will ask Reata Pharmaceuticals and the U.S. Food and Drug Administration to make omaveloxolone (RTA 408) available to people living with Friedrich’s ataxia (FA) — for whom no approved treatments currently exist. The petition — dubbed “a call to action” — asks Reata to submit a new drug application (NDA) for omaveloxolone to the FDA on an urgent basis,…

You must be logged in to read/download the full post.